Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier hit by bone drug safety issues as Mediator continues to make waves

This article was originally published in Scrip

Executive Summary

The French company Servier, already staggering under the weight of the Mediator affair, is again under fire, this time over the safety profile of its osteoporosis drug, Protelos (strontium ranelate). A French committee is examining the pharmacovigilance data on the product to see whether its risk-benefit profile needs to change, and Servier's pharmacovigilance systems are also under the spotlight.

You may also be interested in...



Europe’s Ad Hoc Pandemic Response Highlights Supply Chain Weaknesses

Panelists at a recent virtual session of the DIA’s Europe 2020 conference identified the positive and negative aspects of Europe’s response to the pandemic, and suggested ways of avoiding shortages and making the supply chain more resilient in the event of future crises.

EU Biosimilar Filings, Opinions And Approvals

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Surveillance Data: The Key To Tackling AMR In Africa

A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel